Topiroxostat impurity synthesis method

A technology of topinostat and synthetic method, applied in the field of chemical pharmacy, to achieve the effect of cheap raw materials, simple operation and easy availability of raw materials

Inactive Publication Date: 2016-10-12
JIANGSU YUEXING PHARMA
View PDF4 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] After searching, there is no bibliographical report about the synthesis of this impurity, therefore, it has important practical significance to provide a kind of synthetic method of topirestat for the preparation of impurity standard substance

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Topiroxostat impurity synthesis method
  • Topiroxostat impurity synthesis method
  • Topiroxostat impurity synthesis method

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Example 1: Preparation of methyl 2-cyano-4-pyridinecarboxylate

[0021]

[0022] Add methylisonicotinic acid-N-oxide (2) (15.31g, 0.1mol) and 200ml of acetonitrile into a 250ml three-necked flask and stir to completely dissolve, then add triethylamine (15g, 0.15mol), trimethylsilyl cyanide (29.76g, 0.3mmol) after nitrogen protection reflux reaction for 20 hours, TLC detection reaction ended. The solvent was distilled to dryness under reduced pressure, and the residue was subjected to silica gel column chromatography, eluting with dichloromethane-methanol (50:1), to obtain a white crystal with a yield of 13.48 g, 83.14%.

[0023] 1 HNMR (600 MHz, DMSO-d6, δppm): 4.03 (s, 3H,), 8.11 (d, 1H,), 7.76 (s, 1H), 8.26 (s, 1H), 8.89 (d, 1H).

Embodiment 2

[0024] Embodiment two: the preparation of 2-cyanoisoniazid

[0025]

[0026] Add methyl 2-cyano-4-pyridinecarboxylate (3) (13.48g, 0.083mmol) and 130ml methanol into a 250ml three-necked flask, stir, cool to -5°C in an ice-salt bath, and dropwise add hydrazine hydrate (80%) 13.48 g, react at -5°C for 6 h, and TLC detects that the reaction is complete. Recrystallized with ethanol to obtain 11.12 g of white crystals, with a yield of 82.46%.

[0027] 1 HNMR (600 MHz, DMSO-d6, δppm): 4.77 (s, 2H,), 8.03 (d, 1H,), 8.33 (s, 1H), 8.89 (s, 1H), 10.24 (s, 1H).

Embodiment 3

[0028] Example 3: Preparation of 2-(3-(2-aminopyridin-4-yl)-1H-1,2,4-triazol-5-yl)isoniazid

[0029]

[0030] Add 2-cyanoisoniazid (4) (5.56g, 0.034mmol) and 50ml of methanol into a 100ml three-necked flask and stir, then add sodium methoxide (0.37g, 0.0068mmol), stir at room temperature for 1 hour, then add another part of 2-cyano Isoniazid (4) (5.56g, 0.034mmol) was heated to reflux for 26 hours, and the reaction was detected by TLC. After cooling to room temperature, it was filtered and dried to obtain 9.21 g of a light yellow solid with a yield of 88.42%.

[0031] 1 HNMR (600MHz, DMSO-d6, δppm): 3.49 (s, 2H,), 7.60 (s, 1H,), 7.76 (s, 1H), 8.14 (d, 1H), 8.32 (s, 1H), 8.55 ( s, 1H), 8.80(s, 1H), 8.93(s, 1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses a topiroxostat impurity synthesis method, and belongs to the chemical pharmaceutical technical field. The method comprises the steps: with methyl isonicotinic acid-N-oxide (2) as a starting material, generating 2-cyano-4-pyridine carboxylic acid methyl ester from methyl isonicotinic acid-N-oxide (2) and trimethylsilyl cyanide; carrying out hydrazinolysis of the compound (3) to generate 2-cyano-isoniazid (4); and carrying out ring self-formation of the compound (4) to generate a target 2-(3-(2-amino pyridine-4-yl)-1H-1,2,4-triazole-5-yl)isoniazide (1). The synthesized high-purity topiroxostat impurity can be used as an impurity standard in topiroxostat finished product detection analysis, so as to enhance accurate positioning and qualitation on the impurity in the topiroxostat finished product detection analysis, be conducive to strengthening of the control of the impurity, and improve the quality of the topiroxostat finished product; the method provided by the invention has the advantages of cheap and easily obtained raw materials, and simple operation; the yield of the obtained product is 85%+ / -5%, and the HPLC purity is not less than 98%.

Description

technical field [0001] The invention belongs to the technical field of chemical pharmacy, and in particular relates to a topinastat impurity 2-(3-(2-aminopyridin-4-yl)-1H-1,2,4-triazol-5-yl)isoniacin Synthesis of hydrazine. Background technique [0002] With the development of society and the change of diet structure, the incidence of gout presents an increasing trend. Topirostat (Topiroxostat) was developed by Japan Fuji Pharmaceutical Co., Ltd., and was approved for marketing in Japan in June 2013. Topirostat has a significant inhibitory effect on both oxidized and reduced XOR, so it reduces the activity of uric acid. The effect is more powerful and long-lasting, so this product can be used to treat chronic hyperuricemia of gout. There are two advantages over allopurinol. 1: Allopurinol only has an inhibitory effect on reduced XOR, while topicastat has a significant inhibitory effect on both oxidized and reduced XOR, so its effect of lowering uric acid is more powerful ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): C07D401/14
CPCC07D401/14
Inventor 花海堂翟富民陈海生胡玉乾包华兰
Owner JIANGSU YUEXING PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products